Nicholas Anthony Kerton

EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN.

Celsis International Ltd. develops and supplies medical diagnostic products and laboratory services. The company was founded by Sir Christopher Evans in 1992 and is headquartered in Westminster, the United Kingdom.

Part of Malthus Instruments Ltd. management, Malthus Instruments is a British company that manufactures measuring devices. The private company is based in Chester, UK. Malthus Instruments was acquired by Malthus Instruments. management on May 01, 1994.

Cambridge Cognition Ltd. operates as a neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. It offers CANTAB Tests and Services, CANTAB mobile and CANTABeclipse. The company was founded in 2002 and is headquartered in Cambridge, GB.

Part of Thermo Fisher Scientific, Inc., Maybridge Chemical Holdings Ltd. provides organic compounds and combinatorial libraries for use in drug discovery. The private company is based in Tintagel, UK. Maybridge Chemical Holdings was acquired by Fisher Scientific International, Inc. on November 18, 2002.

Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality.

Lab 21 Ltd. operates as a healthcare diagnostics company. It specializes in providing patients, doctors, hospitals ,and healthcare providers with diagnostic information for disease identification, disease predisposition, and personalized medicine, to help in managing health problems. It also offers diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. The company was founded in April 2005 by Berwyn E. Clarke and is headquartered in Cambridge, the United Kingdom.